Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank33
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-88.13%
↓ 27% vs avg
Percentile
P33
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
-69.42%
Historical baseline
PeriodValueYoY Change
TTM-88.13%+18.7%
2025-108.35%+29.9%
2024-154.52%+0.9%
2023-155.90%-12.7%
2022-138.36%-28.8%
2021-107.39%-246.2%
2020-31.02%-259.2%
201919.49%-55.7%
201843.97%+69.0%
201726.02%-